Insider · SEC Form 4 filer
EcoR1 Capital, LLC
Past buys: 4 of 5 beat
Companies
Where they file as an insider
Atara Biotherapeutics (ATRA) 10% owner Latest filing May 7, 2026
First Tracks Biotherapeutics (TRAX) 10% owner Latest filing Apr 20, 2026
Adaptimmune Therapeutics (ADAP) 10% owner Latest filing Jul 30, 2025
Zymeworks (ZYME) Director, 10% owner Latest filing May 19, 2025
iTeos Therapeutics (ITOS) 10% owner Latest filing May 15, 2025
Prothena Corp Public (PRTA) 10% owner Latest filing May 6, 2025
Anaptysbio (ANAB) Director, 10% owner Latest filing Jan 2, 2025
Mersana Therapeutics (MRSN) 10% owner Latest filing Dec 19, 2024
And 1 more company with older filings.
Track record
Did their buys beat the typical stock?
Open-market buys31
Quarters checked 6 months later5
Beat the typical stock 4 of 5
Quarters too new to check0
4 of 5 checked quarters beat the typical stock. A past record is data, not a forecast.
Zymeworks (ZYME) Bought Apr 1–May 19, 2025 · $3.54M · 307,152 shares Beat typical Jun 30, 2025 $12.55 → Dec 31, 2025 $26.33 · +109.8% (typical stock +2.1%)
Anaptysbio (ANAB) Bought Jan 2, 2025 · $86.1K · 6,646 shares Beat typical Mar 31, 2025 $18.59 → Sep 30, 2025 $30.62 · +64.7% (typical stock +7.3%)
Zymeworks (ZYME) Bought Jan 2–Mar 31, 2025 · $15.3M · 1.15M shares Beat typical Mar 31, 2025 $11.91 → Sep 30, 2025 $17.08 · +43.4% (typical stock +7.3%)
Anaptysbio (ANAB) Bought Dec 30–31, 2024 · $1.01M · 78,452 shares Beat typical Dec 31, 2024 $13.24 → Jun 30, 2025 $22.20 · +67.7% (typical stock −3.4%)
Zymeworks (ZYME) Bought Dec 24–31, 2024 · $4.87M · 335,798 shares Behind typical Dec 31, 2024 $14.64 → Jun 30, 2025 $12.55 · −14.3% (typical stock −3.4%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.